Neil D. Gross
Houston surgeon who led the trial showing that giving cemiplimab before surgery can eliminate cutaneous squamous-cell carcinoma in about half of patients, sparing many from extensive operations.
Overview
Neil Gross is a head and neck surgical oncologist at MD Anderson Cancer Center. He was first author of the 2022 New England Journal of Medicine report of a phase 2 trial of neoadjuvant cemiplimab in resectable stage II to IV cutaneous squamous-cell carcinoma, in which about half of patients had a pathological complete response at surgery, and leads studies of neoadjuvant immunotherapy in head and neck cancers.
Similar pages
not linked directly; found by shared links- PersonMichael R. Migden
Shares Advanced cutaneous squamous cell carcinoma, Skin cancer (all types), MD Anderson Cancer Center and the tags skin, immunotherapy, trialist.
- PersonDanny Rischin
Shares Advanced cutaneous squamous cell carcinoma, Skin cancer (all types), Head and neck squamous cell carcinoma and the tags skin, immunotherapy, trialist.
- PersonJean-Jacques Grob
Shares Advanced cutaneous squamous cell carcinoma, Skin cancer (all types) and the tags skin, immunotherapy, trialist.
- PersonShailender Bhatia
Shares Skin cancer (all types) and the tags skin, immunotherapy, trialist.
- PersonAlexander J. Stratigos
Shares Advanced cutaneous squamous cell carcinoma, Skin cancer (all types) and the tags skin, immunotherapy.
- PersonRobert L. Ferris
Shares Head and neck squamous cell carcinoma and the tags surgery, immunotherapy, trialist.
- PersonAleksandar Sekulic
Shares Skin cancer (all types) and the tags skin, trialist.
- PersonJean-Pascal Machiels
Shares Head and neck squamous cell carcinoma and the tags immunotherapy, trialist.